Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced Renal Cell Carcinoma Published in th

1. Motzer R, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. NEJM. February 16, 2019.Published online ahead of print. 2. National Cancer Institute: SEER Stat Fact Sheets: Kidney and renal pelvis. Available from: http://seer.cancer.gov/statfacts/html/ki... [http://seer.cancer.gov/statfacts/html/ki...]. Accessed February 2019. 3. American Cancer Society. What is kidney cancer? Available from: https://www.cancer.org/cancer/kidney-cancer/about.html [https://www.cancer.org/cancer/kidney-cancer/about.html]. Accessed February 2019. 4. Escudier B, Porta C, Schmidinger M et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol. 2014; 25(Suppl3):iii49-iii56. 5. American Cancer Society. Cancer facts and figures 2019. Available at: https://www.cancer.org/content/dam/cancer-org/research/cance... tatistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2 019.pdf [https://www.cancer.org/content/dam/cancer-org/research/cance...- statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures- 2019.pdf]. Accessed February 2019. 6. Ljungberg B, Campbell S and Cho H. The Epidemiology of Renal Cell Carcinoma. Eur Urol. 2011;60:615-621. 7. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231-237. 8. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc Rs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295. 9. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148-1157. 10. Kohrt HE, Houot R, Marabelle A, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4(5):511-527. 11. Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017;17(4):515-523.

Your Contacts Merck Media Relations: +1 781 427 4351 noelle.piscitelli@emdserono.com Investor Relations: +49 6151 72 3321 investor.relations@merckgroup.com Pfizer Media Relations: +1 212 733 6213 jessica.m.smith@pfizer.com Investor Relations: +1 212 733 8160 ryan.crowe@pfizer.com

Logo -- https://mma.prnewswire.com/media/611425/... [https://mma.prnewswire.com/media/611425/...]